Oncogenex Pharmaceuticals Inc (OGXI) 3.91 $OGXI
The Biggest Biotech Catastrophes of the Week
Cory Renauer, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
Last week was rough for clinical stage biotechnology companies. Three watched their market caps dissolve after reporting lead candidate failures. Endocyte had an abrupt reversal of fortune, while OncoGenex Pharmaceuticals found out its...
The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
at The Street - Tue May 06, 9:00AM CDT
The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million.
OncoGenex Posts Wider Loss, Beats Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:20PM CDT
OncoGenex (OGXI) reported a loss of 59 cents/share in 1Q14, wider than the Zacks Consensus Estimate of a loss of 44 cents and the year-ago loss of 46 cents.
5 Stocks Under $10 Set to Soar
at The Street - Thu May 01, 1:30PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2014
PR Newswire - Wed Apr 30, 3:00PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and anticipated near-term milestones and announced first quarter 2014 financial results.
OncoGenex's Custirsen Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:29PM CDT
Shares of OncoGenex (OGXI) tumbled 60.3% after it announced that its lead candidate, custirsen, failed to meet its primary endpoint in the phase III, SYNERGY study.
Downgrade Alert for OncoGenex Pharmaceutical (OGXI)
Comtex SmarTrend(R) - Tue Apr 29, 6:56AM CDT
OncoGenex Pharmaceutical (NASDAQ:OGXI) was downgraded from Outperform to Sector Perform at RBC Capital today. The stock closed yesterday at $3.85 on volume of 3.7 million shares, above average daily volume of 253,000. OncoGenex Pharmaceutical Inc. is a biopharmaceutical company that develops and commercializes new cancer therapies that address treatment resistance in cancer patients.
Down 60%: Is OncoGenex a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Apr 28, 5:32PM CDT
Shares of OncoGenex Pharmaceuticals (NASDAQ: OGXI) were crushed today, after the company's most advanced drug candidate, Custirsen, flopped in a phase 3 trial. The drug did not improve median overall survival, the primary endpoint of its...
Nasdaq stocks posting largest volume increases
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why OncoGenex (OXGI) Stock Hit a One-Year Low Today
at The Street - Mon Apr 28, 1:37PM CDT
OncoGenex (OXGI) plummeted to a one-year low after the company announced its experimental prostate cancer treatment failed to show any statistically significant improvements in a late-stage trial.
Investors look to Lighten Up on Shares of OncoGenex Pharmaceutical, Shares Down 50.1% (OGXI)
Comtex SmarTrend(R) - Mon Apr 28, 10:10AM CDT
OncoGenex Pharmaceutical (NASDAQ:OGXI) is one of today's worst performing low-priced stocks, down 50.1% to $4.84 on 5.7x average daily volume. Thus far today, OncoGenex Pharmaceutical has traded 1.4 million shares, vs. average volume of 250,000 shares per day. The stock has underperformed the Dow (-50.1% to the Dow's 0.7%) and underperformed the S&P 500 (-50.1% to the S&P's 0.5%) during today's trading.
OncoGenex to Report Financial Results for First Quarter 2014 on April 30, 2014
CNW Group - Mon Apr 28, 6:15AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first quarter 2014 financial results will be released on Wednesday, April 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer
CNW Group - Mon Apr 28, 6:10AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced results from the Phase 3 SYNERGY trial. Top-line survival results indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer (CRPC), compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively; hazard ratio 0.93 and one-sided p value 0.207). The adverse events observed were similar to custirsen's known adverse event profile.
Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer
Business Wire - Mon Apr 28, 6:02AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer (CRPC).
OncoGenex Gains Fast Track Status for Custirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:50PM CDT
FDA granted Fast Track status to OncoGenex Pharmaceuticals, Inc.'s (OGXI) oncology candidate, custirsen
The Biggest Biotech Catastrophes of the Week
Cory Renauer, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
Last week was rough for clinical stage biotechnology companies. Three watched their market caps dissolve after reporting lead candidate failures. Endocyte had an abrupt reversal of fortune, while OncoGenex Pharmaceuticals found out its...
The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
at The Street - Tue May 06, 9:00AM CDT
The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million.
OncoGenex Posts Wider Loss, Beats Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 4:20PM CDT
OncoGenex (OGXI) reported a loss of 59 cents/share in 1Q14, wider than the Zacks Consensus Estimate of a loss of 44 cents and the year-ago loss of 46 cents.
5 Stocks Under $10 Set to Soar
at The Street - Thu May 01, 1:30PM CDT
These under-$10 stocks look ready to trade higher from current levels.
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2014
PR Newswire - Wed Apr 30, 3:00PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and anticipated near-term milestones and announced first quarter 2014 financial results.
OncoGenex's Custirsen Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 5:29PM CDT
Shares of OncoGenex (OGXI) tumbled 60.3% after it announced that its lead candidate, custirsen, failed to meet its primary endpoint in the phase III, SYNERGY study.
Downgrade Alert for OncoGenex Pharmaceutical (OGXI)
Comtex SmarTrend(R) - Tue Apr 29, 6:56AM CDT
OncoGenex Pharmaceutical (NASDAQ:OGXI) was downgraded from Outperform to Sector Perform at RBC Capital today. The stock closed yesterday at $3.85 on volume of 3.7 million shares, above average daily volume of 253,000. OncoGenex Pharmaceutical Inc. is a biopharmaceutical company that develops and commercializes new cancer therapies that address treatment resistance in cancer patients.
Down 60%: Is OncoGenex a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Mon Apr 28, 5:32PM CDT
Shares of OncoGenex Pharmaceuticals (NASDAQ: OGXI) were crushed today, after the company's most advanced drug candidate, Custirsen, flopped in a phase 3 trial. The drug did not improve median overall survival, the primary endpoint of its...
Nasdaq stocks posting largest volume increases
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why OncoGenex (OXGI) Stock Hit a One-Year Low Today
at The Street - Mon Apr 28, 1:37PM CDT
OncoGenex (OXGI) plummeted to a one-year low after the company announced its experimental prostate cancer treatment failed to show any statistically significant improvements in a late-stage trial.
Investors look to Lighten Up on Shares of OncoGenex Pharmaceutical, Shares Down 50.1% (OGXI)
Comtex SmarTrend(R) - Mon Apr 28, 10:10AM CDT
OncoGenex Pharmaceutical (NASDAQ:OGXI) is one of today's worst performing low-priced stocks, down 50.1% to $4.84 on 5.7x average daily volume. Thus far today, OncoGenex Pharmaceutical has traded 1.4 million shares, vs. average volume of 250,000 shares per day. The stock has underperformed the Dow (-50.1% to the Dow's 0.7%) and underperformed the S&P 500 (-50.1% to the S&P's 0.5%) during today's trading.
OncoGenex to Report Financial Results for First Quarter 2014 on April 30, 2014
CNW Group - Mon Apr 28, 6:15AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first quarter 2014 financial results will be released on Wednesday, April 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OncoGenex Announces Top-Line Survival Results of Phase 3 SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-Resistant Prostate Cancer
CNW Group - Mon Apr 28, 6:10AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced results from the Phase 3 SYNERGY trial. Top-line survival results indicate that the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer (CRPC), compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively; hazard ratio 0.93 and one-sided p value 0.207). The adverse events observed were similar to custirsen's known adverse event profile.
Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer
Business Wire - Mon Apr 28, 6:02AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer (CRPC).
OncoGenex Gains Fast Track Status for Custirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:50PM CDT
FDA granted Fast Track status to OncoGenex Pharmaceuticals, Inc.'s (OGXI) oncology candidate, custirsen
